Objective:
Report real-world safety and outcomes over 2 years after biointerventional uveoscleral outflow enhancement.
Approach:
- Study population: The presentation described outcomes in 575 eyes treated with AlloFloUveo (Iantrek).
- Follow-up: Safety, bleb-forming surgery, intraocular pressure (IOP), and medication use were reported at 2 years.
Key Findings:
- The reported adverse event rate at 2 years was 15%.
- At 2 years, 65% of eyes that otherwise would have been considered for bleb-forming surgery remained free of such procedures.
- IOP was approximately 30% lower than baseline, and medication use was reduced by one medication from baseline.
Interpretation:
Presenter Reena A. Garg, MD, characterized the procedure as safe and effective and said it could delay or postpone the need for bleb-forming procedures.
Limitations:
- The provided transcript does not describe study design, patient characteristics, adverse-event details, or statistical analyses.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.